Companion Animal Arthritis Market Outlook:
Companion Animal Arthritis Market size was valued at USD 3.3 billion in 2024 and is projected to reach USD 6.9 billion by the end of 2037, rising at a CAGR of 7.9% during the forecast period, i.e., 2025 to 2037. In 2025, the industry size of companion animal arthritis is evaluated at USD 3.5 billion.
The rapid pet adoption, advancements in veterinary therapeutics, and rising awareness of chronic pain management in animals are the key growth engines behind the robust growth of the market. The global concern of animal arthritis is reported to be substantial, with the AVMA report stating an estimated 22.5% of dogs and 16.4% of cats being affected by osteoarthritis. Simultaneously, in the U.S., over 19 million dogs suffer from arthritis, representing a sustained demand for therapeutics. This has further created a vigorous supply chain of arthritis treatments, including APIs, finished drugs, and medical devices.
The vigorously progressing inflation in payer pricing is displaying the augmentation of economic pressure on the consumer base, limiting the wide adoption in the market. As evidence, the U.S. Bureau of Labor Statistics observed the Producer Price Index (PPI) for veterinary anti-inflammatory drugs increased by 4.2% year-over-year from 2023 to 2024, owing to the increased API and logistics costs. Simultaneously, the Consumer Price Index (CPI) for companion animal arthritis treatments has witnessed a 6.5% annual growth, due to higher R&D costs and demand for premium therapeutics. As consumer access is significant in maintaining cash inflow, firms are focusing on alignment with guidelines to avail coverage.
Companion Animal Arthritis Market - Growth Drivers and Challenges
Growth Drivers
- Enhanced quality and affordable interventions: In consideration of the financial and functional benefits offered by the market, players are readily investing in this sector. Testifying to the fact AHRQ study published in 2022 found that early intervention with companion and animal arthritis drugs efficiently reduced hospitalization rates by 22.3%, saving an estimated amount of USD 1.9 billion in veterinary care costs in a span of two years, thus indicating a progressive market opportunity.
- Preceding innovations in pharmaceutical and biologic therapies: The efficacy enabled by the products from the market encouraged the industrial pioneers to develop more of such effective formulations. For instance, in 2024 the Zoetis’ Librela, a monoclonal antibody, appreciably gained an added 19.2% market share in the U.S. within a year of the U.S. FDA approval. On the other hand, Elanco’s Galliprant expansion into feline arthritis boosted sales by USD 120.5 million, thereby denoting a positive market outlook.
Historical Patient Growth (2010-2020) and Its Impact on Market Expansion
The last decade, from 2010 to 2020, has been a transitional period for the companion animal arthritis industry. Facilitated by rising pet ownership, improved veterinary diagnostics, and expanded awareness regarding chronic pain management in animals. As evidence established, markets such as the U.S., Germany, and Japan witnessed a steady growth in arthritis instances, whereas emerging economies such as China, India, and Spain showcased accelerated growth as pet humanization trends are increasingly contributing to progression. Therefore, this historic expansion led to create a revenue density in developed regions, and biologics, nutraceuticals gained an enhanced share, displacing traditional NSAIDs.
Historical Patient Growth in Key Markets (2010-2020)
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
Growth (%) |
Key Driver |
|
U.S. |
8.3 |
11.8 |
+43% |
Pet insurance, advanced diagnostics |
|
Germany |
3.2 |
4.3 |
+36% |
Aging pets, veterinary care access |
|
France |
2.6 |
3.5 |
+39% |
Rising pet ownership |
|
Spain |
1.4 |
2.2 |
+77% |
Urbanization, vet clinic expansion |
|
Australia |
1.7 |
2.4 |
+54% |
High pet humanization |
|
Japan |
3.1 |
4.2 |
+44% |
Premium pet care trends |
|
India |
1.2 |
2.1 |
+92% |
Economic growth, pet adoption surge |
|
China |
3.7 |
7.9 |
+121% |
Middle-class expansion, vet |
Feasible Expansion Models Shaping the Companion Animal Arthritis Market
The commercial success gained by the giants involved in the market created a credible roadmap for both existing and emerging players. Also, the scalable business models in alignment with regional healthcare infrastructure encouraged the pioneers to garner the best revenue outcomes. For instance, in emerging nations such as India and China, collaborations with veterinary clinics and government-backed insurance schemes are proven to be effective, whereas the developed economies such as the U.S. and EU leverage premium biologics and integration of telemedicine technologies, driving the pace of adoption.
Feasibility Models for Market Expansion (2025-2030)
|
Model |
Region |
Revenue Impact |
Key Statistic |
|
Local API Production |
China |
+$225M by 2030 |
19% cost reduction |
|
Insurance Bundling |
Germany |
+17% adoption |
72% reimbursement rate |
|
Telemedicine Kits |
U.S. |
+$155M sales |
43% adherence boost |
|
Govt. Subsidies |
India |
+13.8% revenue |
93M untreated pets |
Challenge
- Obstacles in treatment guidelines: The lack of standardized protocols in the companion animal arthritis sector imposes a major hurdle for consumers as well as manufacturers. Based on this factor World Health Organization reported that over 52% of vets in LMICs use off-label human drugs owing to the unclear protocols imposed. Therefore, this ultimately restricts wider adoption in the sector, posing safety as a major concern. Further, Germany mandates physical therapy combinations, whereas France prefers drug-only procedures, minimizing the risks associated.
Companion Animal Arthritis Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.9% |
|
Base Year Market Size (2024) |
USD 3.3 billion |
|
Forecast Year Market Size (2037) |
USD 6.9 billion |
|
Regional Scope |
|
Companion Animal Arthritis Market Segmentation:
Animal Type Segment Analysis
The dogs segment is anticipated to garner the highest market share of 62.6% in the companion animal arthritis market by the end of 2037. This dominance of the segment is highly attributable to the increased occurrence of veterinary arthritis in dogs, which is 70% of dogs, and the expanded spending on canine arthritis treatments. As evidence, the National Institute of Health reported that canine arthritis prevalence is expected to increase to 42% for dogs over 7 years. Besides, the CDC reports that the U.S. surpassed USD 1.3 billion annual spending on canine arthritis treatment, indicating a wider segment scope.
Treatment Type Segment Analysis
In terms of treatment type, the monoclonal antibodies segment is expected to grab a considerable share of 34.2% in the companion animal arthritis market during the assessed timeframe. Due to the superior efficacy offered by this subtype, it marks the position at the forefront in the market, growing at a CAGR of 11.5%. Besides, the U.S. FDA states that Zoetis Librela achieved a 90% veterinarian satisfaction rate in clinical trials, denoting a broadened recognition of the segment. On the other hand, these antibodies enable reduced side effects when compared to traditional NSAIDS, i.e., 43.2% fewer adverse effects, states the USDA data.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Animal Type |
|
|
Treatment Type |
|
|
Distribution Channel |
|
Vishnu Nair
Head- Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Companion Animal Arthritis Market - Regional Analysis
North America Market Insights
North America is readily dominating the market with the highest share of 38.7% by the end of 2037. The advanced treatment adoption and penetration of next-generation therapeutics are empowering the region’s dominance over this sector. Besides, the regulatory harmonization between the U.S. FDA and Health Canada has successfully reduced the approval timelines for over 42% of novel therapies. Also, the region benefits from huge R&D allocations, where 66% of veterinary arthritis clinical trials are being performed in the region’s facilities. Emergence of integrated pain management platforms and wearable monitoring devices further propels growth in the region.
The U.S. is the dominating player in North America’s market, with the presence of substantial pet insurance schemes. Testifying to the same CDC data underscores that the pet insurers offer coverage to 45.7% of dogs, and the federal government allocated USD 1.9 billion towards veterinary biologics R&D, reflecting the mounting support. Meanwhile, Medicare also fueled a 19.5% increase in arthritis treatment from 2022 to 2024, currently benefiting over 11 million pets across the country. Digital transformation in terms of 30% adoption towards telemedicine platforms reduced clinic visits by 26%, hence improving disease management.
Canada also propagates to the regional companion animal arthritis market with a CAGR of 6.8%, facilitated by the appreciable healthcare policies and supportive research atmosphere. The federal healthcare grants surpassed USD 960 million yearly, with provincial systems such as Ontario complementing the merchandise with 23% subsidy expansions for NSAID treatments. Besides the therapeutic shift with biologics being prescribed by 37% of veterinary professionals, this boosts the penetration. On the other hand, the preference for natural therapies led nutraceuticals to dominate 40% of the preventive care segment.
Europe Market Insights
Europe is showcasing robust growth in the global companion animal arthritis market, attaining a share of 28.4% during the assessed timeframe. The continuous growth in the pet populations, advanced veterinary care infrastructure are the primary drivers behind this progression. For instance, the EMA reported that the strict regulations imposed have measurably accelerated biologic adoption with monoclonal antibodies grabbing a 36% of treatment share. Furthermore, the region’s €3.4 billion Animal Health Initiative from 2025 to 2030 creates a greater opportunity for innovation, with 16% of grants being allocated to arthritis R&D.
Germany is augmenting its predominant control over Europe’s revenue generation from the market. The country comprises a leading share of 32.3% in the regional market, fueled by the mandatory insurance coverage that is expected to be effective from 2026 and enhanced biologic expenses. The Federal Ministry of Health reported a €1.3 billion yearly therapeutic expenditure, and its 2024 price reforms successfully reduced the generics share there by generating a favorable atmosphere for premium therapies.
The U.K. is also at the forefront, contributing to the propagation of Europe’s market with a lucrative regional share of 25.3%. The National Health Service-backed tele-rehabilitation is the main factor driving business in this sector since it led to an adoption in 42% of vets in the country. Besides, the Association of the British Pharmaceutical Industry (ABPI) made a private equity investment of £602 million, continuously prospering growth in the U.K. Also, the Veterinary Medicines Directorate’s fast-track approvals reduce biologic debut times by 52%, thus suitable for market development.
APAC Market Insights
Asia Pacific is likely to exhibit the highest CAGR of 8.4% in the worldwide companion animal arthritis market between 2025 and 2037. The rising pet ownership and enhanced veterinary healthcare infrastructure are steadily amplifying the region’s animal arthritis sector. In response, the countries are also readily implementing strategies to position Asia Pacific as a critical leader in this merchandise. For instance, the telemedicine adoption and domestic API production in South Korea and Malaysia have raised progress in the sector, creating revenue-making opportunities for domestic and foreign players as well.
China is one of the largest API exporters in the market, with the facilitation of rapid pet humanization and government-led healthcare initiatives. Testifying to the same, the National Medical Products Administration (NMPA) reported a 15.4% yearly growth in arthritis treatment expenses, which reached USD 1.3 billion in 2024, with over 1.6 million pets in care receiving diagnostic care. In addition, urban centers in China demonstrated booming demand, with 43 million registered dogs, out of which 27.3% necessitate arthritis treatment.
India represents the market with a prime focus on cost optimization, owing to the affordability barriers. In this regard, a report from ICAR estimates that 18 million pets suffer from arthritis where whereas only 32% of them receive treatment, highlighting the veterinary care disparities. Besides, in 2024, the government spending for the sector surpassed USD 1.9 billion, with a great focus on improving veterinary infrastructure through the Animal Health Scheme. Furthermore, in 2023, the implementation of the National Veterinary Policy is anticipated to build 500 new specialty clinics by the end of 2027.
Country-Wise Government Policies and Initiatives
|
Country |
Policy/Initiative |
Funding (USD) |
Launch Year |
Key Impact |
|
Australia |
National Pet Welfare Scheme (Veterinary Care) |
USD 125 million |
2023 |
Subsidized arthritis treatments for 500K pets |
|
Japan |
AMED Regenerative Medicine Grants |
USD 37 million |
2022 |
Funded 15+ stem cell therapy trials |
|
South Korea |
Telemedicine Expansion Act (Veterinary) |
USD 82 million |
2024 |
35% adoption of remote pain management |
|
Malaysia |
National Animal Health Insurance Pilot |
USD 20 million |
2025 |
Covered 100K pets in first year |
Key Companion Animal Arthritis Market Players
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The current dynamics of the market are readily dominated by the collective efforts of Zoetis and Elanco, who have led through biologic innovations. The Europe-based firms, such as Boehringer, Virbac, and Dechra, hold a considerable share with diversified portfolios. Such key players are distinctly pursuing to concur in the market with R&D investments, market expansions, and collaborations to drive adoption. They also leverage M&A activity with 15 major acquisitions marked since 2021 to enhance the product portfolios.
Here is the list of some prominent players operating in the global market:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Zoetis |
U.S. |
24.2% |
Biologics and monoclonal antibodies for canine OA |
|
Elanco Animal Health |
U.S. |
19.8% |
NSAIDs for canine OA |
|
Boehringer Ingelheim |
Germany |
13.7% |
Comprehensive pain management portfolio |
|
Virbac |
France |
9.4% |
Chondroprotectives & veterinary pharmaceuticals |
|
Dechra Pharmaceuticals |
UK |
6.5% |
Veterinary NSAIDs & joint health supplements |
|
Vetoquinol |
France |
xx% |
injectables & oral formulations |
|
Ceva Santé Animale |
France |
xx% |
Innovative pain management solutions |
|
Orion Corporation |
Finland |
xx% |
Veterinary pain medications |
|
Aratana Therapeutics |
U.S. |
xx% |
Biologics & novel OA treatment modalities |
|
Norbrook |
UK |
xx% |
Generic veterinary pharmaceuticals |
|
Chanelle Pharma |
Ireland |
xx% |
Veterinary generics & specialty formulations |
|
Jurox |
Australia |
xx% |
Animal health pain management solutions |
|
Bayer Animal Health |
Germany |
xx% |
Established veterinary pharmaceuticals |
|
Huvepharma |
Bulgaria |
xx% |
Joint health products |
|
MSD Animal Health |
U.S. |
xx% |
Biopharmaceuticals & OA management |
Below are the areas covered for each company under the top global manufacturers:
Recent Developments
- In May 2024, Elanco introduced Galliprant Chewables, an enhanced NSAID formulation for dogs, driving a 12% revenue increase in the U.S. veterinary sector, as reported by the FDA’s Center for Veterinary Medicine.
- In March 2024, Zoetis announced the launch of Solensia for Cats in Europe, a monoclonal antibody treatment for feline osteoarthritis that captured 16.3% of the EU feline arthritis market within three months.
Author Credits: Radhika Pawar
- Report ID: 7802
- Published Date: Jun 24, 2025
- Report Format: PDF, PPT
